サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541802

免疫調節剤市場レポート：製品・用途・地域別、2024～2032年

Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
免疫調節剤市場レポート：製品・用途・地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の免疫調節剤市場規模は、2023年に2,112億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに3,314億米ドルに達し、2024～2032年の間に5％の成長率（CAGR）を示すと予測しています。

免疫調節剤は、感染症、免疫不全、抗体伝達の変化に対する免疫反応を修正するために使用される薬剤群です。これらの薬剤には一般に、モノクローナル抗体、サイトカイン、レバミソール、カルメット菌ゲリン（BCG）などが含まれます。これらはがん、喘息、腫瘍、遺伝性血管性浮腫、天疱瘡、ループス、アレルギー、関節リウマチなどの自己免疫疾患の治療に広く使用されています。最近では、炎症性腸疾患（IBD）の管理に、免疫調節薬と生物製剤などの他の薬剤を併用することを推奨する医療プロバイダーも増えています。

免疫調節剤市場傾向

急速な都市化、所得水準の高騰、加工食品の消費量の増加などを背景とした個人の不健康なライフスタイルは、世界の慢性疾患の有病率の著しい上昇につながっています。これは臓器移植の必要性をさらに高めており、臓器移植を受けた患者における有望な治療として、局所免疫調節薬の需要にプラスの影響を与えています。さらに、高齢化人口の増加と事故の増加も臓器不全のリスクを高めています。その結果、臓器提供を奨励する政府機関や非政府機関が相次ぎ、これが局所免疫調節薬の世界の売上を押し上げています。これとは別に、IBDや自己免疫疾患の有病率の増加が市場の成長を後押ししています。免疫調節剤はまた、ステロイドの長期的な必要性を減らし、再燃の再発を予防し、抗生物質が効かない疾患を治療するための併用療法にも利用されています。さらに、フルボキサミン、トシリズマブ、バリシチニブとレムデシビルなどの免疫調節薬は、コロナウイルス病（COVID-19）の入院患者の治療に応用されています。これ以外にも、いくつかの製品候補が現在後期臨床試験段階にあります。これらの製品の開発により、生命を脅かす様々な疾患の治療に対する免疫調節剤の用途が拡大することが期待されます。

本レポートで扱う主要質問

  • 世界の免疫調節剤市場はこれまでどのように推移してきたか？
  • COVID-19は世界の免疫調節剤市場にどのような影響を与えているか？
  • 主要地域市場とは？
  • 製品別の市場内訳は？
  • 用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の免疫調節剤市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の免疫調節剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 免疫抑制剤
    • 市場動向
    • 主要セグメント
      • 抗体
      • カルシニューリン阻害剤
      • グルココルチコイド
      • 代謝拮抗物質
      • その他
    • 市場予測
  • 免疫刺激剤
    • 市場動向
    • 主要セグメント
      • ワクチン
      • 抗体
      • その他
    • 市場予測

第7章 市場内訳：用途別

  • 腫瘍
  • 呼吸器
  • HIV
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Immunomodulators Market: Major Drivers and Challenges
  • Figure 2: Global: Immunomodulators Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immunomodulators Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immunomodulators Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Immunomodulators Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Immunomodulators Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Immunomodulators (Immunosuppressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Immunomodulators (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Immunomodulators (Immunostimulants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Immunomodulators (Immunostimulants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Immunomodulators (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Immunomodulators (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Immunomodulators (Respiratory) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Immunomodulators (Respiratory) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Immunomodulators (HIV) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Immunomodulators (HIV) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Immunomodulators (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Immunomodulators (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: North America: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: North America: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: United States: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: United States: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Canada: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Canada: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Asia-Pacific: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Asia-Pacific: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: China: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: China: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Japan: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Japan: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: India: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: India: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: South Korea: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: South Korea: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Australia: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Australia: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Indonesia: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Indonesia: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Others: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Others: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Europe: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Europe: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Germany: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Germany: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: France: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: France: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: United Kingdom: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: United Kingdom: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Italy: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Italy: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Spain: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Spain: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Russia: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Russia: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Latin America: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Latin America: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Brazil: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Brazil: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Mexico: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Mexico: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Middle East and Africa: Immunomodulators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Middle East and Africa: Immunomodulators Market: Breakup by Country (in %), 2023
  • Figure 67: Middle East and Africa: Immunomodulators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Global: Immunomodulators Industry: SWOT Analysis
  • Figure 69: Global: Immunomodulators Industry: Value Chain Analysis
  • Figure 70: Global: Immunomodulators Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunomodulators Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Immunomodulators Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Immunomodulators Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Immunomodulators Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Immunomodulators Market: Competitive Structure
  • Table 6: Global: Immunomodulators Market: Key Players
目次
Product Code: SR112024A4055

The global immunomodulators market size reached US$ 211.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 331.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.

Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).

Immunomodulators Market Trends:

The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global immunomodulators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.

Breakup by Product:

Immunosuppressants

Antibodies

Calcineurin Inhibitors

Glucocorticoids

Antimetabolites

Others

Immunostimulants

Vaccines

Antibodies

Others

Breakup by Application:

Oncology

Respiratory

HIV

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

  • How has the global immunomodulators market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global immunomodulators market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global immunomodulators market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunomodulators Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Immunosuppressants
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Calcineurin Inhibitors
      • 6.1.2.3 Glucocorticoids
      • 6.1.2.4 Antimetabolites
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Immunostimulants
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Vaccines
      • 6.2.2.2 Antibodies
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Respiratory
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 HIV
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biogen Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bristol-Myers Squibb Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Johnson & Johnson
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis